Alex Rodriguez TRT: Legal and Disclosure Obligations Explained

What Alex Rodriguez's Testosterone Use Actually Involved

Rodriguez admitted in a 2009 ESPN interview to using a substance he called "boli," described as a banned performance-enhancing substance obtained in the Dominican Republic, during his Texas Rangers years from 2001 to 2003. A 2003 MLB survey test, intended to be anonymous, later identified him as one of 104 players who tested positive for testosterone or other anabolic agents. Sports Anti-Doping Research has confirmed that testosterone esters produce urinary testosterone-to-epitestosterone (T/E) ratios exceeding the 4:1 WADA threshold within hours of administration.

The 2003 Survey Test

The 2003 MLB survey was not subject to individual penalties. Its sole purpose was to determine whether more than 5% of players tested positive, which would trigger mandatory testing the following season. That threshold was exceeded, and MLB implemented mandatory random testing in 2004. The anonymity of those samples was challenged in federal court when the U.S. Government subpoenaed the records. The Ninth Circuit ultimately ruled in 2011 that the government's seizure of the entire sample list violated Fourth Amendment protections, though Rodriguez had already been publicly identified.

The Biogenesis Investigation

A decade later, Rodriguez became the central figure in MLB's Biogenesis investigation. Biogenesis of America, a Miami-area anti-aging clinic operated by Anthony Bosch, supplied testosterone, human growth hormone (HGH), and peptides to multiple MLB players. MLB's investigation relied on clinic records, text messages, and witness testimony rather than a positive urine test. Research published in the Journal of Clinical Endocrinology and Metabolism confirms that injectable testosterone cypionate produces detectable metabolites in urine for 14 to 22 days post-injection, depending on dose and individual metabolism. Rodriguez received a 211-game suspension, the longest non-lifetime ban in MLB history, later reduced to 162 games on appeal.

The Federal Legal Framework for Testosterone

Testosterone is not legally equivalent to a supplement or a standard pharmaceutical. The Anabolic Steroid Control Act of 1990, codified at 21 U.S.C. § 802(41), classifies testosterone and its esters as Schedule III controlled substances. That classification means unauthorized manufacture, distribution, or possession with intent to distribute carries felony penalties of up to five years for a first offense.

Schedule III Classification and What It Means

Schedule III status requires DEA registration for any prescriber, pharmacist, or manufacturer handling testosterone. A patient receiving testosterone cypionate 100 mg/week for diagnosed hypogonadism is entirely within the law. An athlete obtaining testosterone from a clinic without a legitimate diagnosis, or receiving it from a non-licensed source like Biogenesis, is committing a federal crime regardless of the therapeutic framing.

The FDA's prescribing information for testosterone products explicitly states that testosterone is indicated for males with primary or hypogonadotropic hypogonadism confirmed by clinical and laboratory findings. Using it for athletic performance enhancement falls outside that indication and constitutes off-label use that, when combined with illegitimate prescribing, triggers DEA enforcement exposure.

The DEA's Role in Anti-Doping Enforcement

DEA agents participated directly in the Biogenesis investigation. Anthony Bosch pleaded guilty in 2014 to conspiracy to distribute testosterone and HGH, receiving a four-year federal prison sentence. Other clinic staff faced similar charges. This outcome illustrates that anti-doping violations in professional sports can translate into federal criminal prosecutions, not just league suspensions.

A 2014 DEA enforcement overview documented that Operation Raw Deal, a prior federal investigation into steroid distribution networks, resulted in 143 arrests and the seizure of 56 steroid labs across 27 states. The Biogenesis case followed a similar multi-agency model.

MLB's Anti-Doping Rules and Testosterone

MLB's Joint Drug Prevention and Treatment Program governs testosterone testing. The program classifies testosterone as a "Performance Enhancing Substance" (PES), subject to the T/E ratio testing standard set by WADA at 4:1. A T/E ratio above 4:1 triggers confirmation testing using isotope-ratio mass spectrometry (IRMS) to distinguish synthetic from endogenous testosterone.

Therapeutic Use Exemptions in MLB

An MLB player with documented hypogonadism may apply for a Therapeutic Use Exemption (TUE). The process mirrors the WADA TUE framework: the player must submit medical records demonstrating a confirmed diagnosis, evidence that no reasonable alternative treatment exists, and documentation that the prescribed dose restores physiological (not supraphysiological) testosterone levels. WADA's 2021 TUE guidelines specify that testosterone TUEs require morning serum total testosterone below 12.1 nmol/L (approximately 350 ng/dL) on two separate occasions, measured by a certified laboratory.

A player granted a TUE is not exempt from all testing. The exemption covers only the approved substance at the approved dose. Any deviation, including dose escalation or co-administration of other substances, voids the TUE and results in a positive test.

How Rodriguez's Case Differed from a Legitimate TUE

Rodriguez never applied for or received a TUE for testosterone during the relevant periods. The substances documented in the Biogenesis records, including testosterone troches and HGH, were obtained outside any sanctioned medical process. MLB Commissioner Bud Selig stated at the time: "There is no justification for what Alex Rodriguez did." That absence of a TUE meant no legal protection existed for his testosterone use under MLB rules or under federal law.

Medical Disclosure Obligations for TRT Patients

For patients outside professional sports, the disclosure obligations around TRT are governed by a different set of rules. HIPAA protects medical information from unauthorized disclosure. A patient receiving testosterone cypionate for diagnosed hypogonadism has no obligation to disclose that treatment to an employer, insurer (with some exceptions), or the general public.

When Disclosure Becomes Required

Disclosure requirements shift in several specific contexts. Commercial drivers holding a CDL must disclose testosterone therapy to their medical examiner under FMCSA regulations, because testosterone can affect hematocrit, sleep apnea risk, and cardiovascular parameters. Military personnel are prohibited from using testosterone without command medical authorization. Federal employees in safety-sensitive positions may face disclosure requirements under DOT drug testing frameworks.

A 2022 review in the Journal of Clinical Endocrinology and Metabolism found that exogenous testosterone suppresses endogenous luteinizing hormone and follicle-stimulating hormone, a physiologic change that standardized workplace drug tests do not detect, because those tests screen for synthetic hormones rather than T/E ratios. This means a standard 5-panel workplace drug test will not flag therapeutic testosterone.

Physician Disclosure Obligations

The prescribing physician carries distinct obligations. DEA regulations require that testosterone prescriptions include a legitimate medical indication documented in the patient record. Prescribing testosterone for "optimization" or "anti-aging" in a patient with normal testosterone levels (generally above 300 ng/dL by most laboratory reference ranges) without documented symptoms of hypogonadism raises regulatory risk for the prescriber.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We suggest against starting testosterone therapy in patients who are planning fertility in the near future, and we recommend measuring hematocrit before starting testosterone therapy." Failure to conduct baseline labs and document the clinical rationale exposes the prescribing physician to DEA scrutiny and state medical board complaints.

TRT Protocols: What Legitimate Therapy Looks Like

Understanding what appropriate TRT looks like clinically separates legal treatment from the performance-enhancement use documented in the Rodriguez case. Legitimate TRT targets restoration of serum testosterone to mid-normal physiological range, typically 400 to 700 ng/dL total testosterone, not supraphysiological levels above 1,000 ng/dL.

Standard Dosing Parameters

The most commonly prescribed regimen in the United States is testosterone cypionate or testosterone enanthate 100 to 200 mg intramuscularly every 7 to 14 days. Testosterone gel formulations (AndroGel 1.62%, Testim) deliver 20.25 to 40.5 mg of testosterone daily via transdermal absorption. Pellet implants (Testopel) release testosterone over 3 to 6 months.

A 2010 randomized controlled trial published in the New England Journal of Medicine (N=209) demonstrated that testosterone gel dosed to achieve serum levels of 500 to 800 ng/dL improved sexual function, physical function, and mood scores compared to placebo over 6 months, with a statistically significant increase in hematocrit that required monitoring.

Monitoring Requirements

Appropriate TRT requires monitoring at 3 months after initiation and annually thereafter. Labs include serum total testosterone (target: 400 to 700 ng/dL), hematocrit (hold if above 54%), PSA (in men over 40), and lipid panel. The American Urological Association's 2018 guidelines on testosterone deficiency recommend against initiating testosterone in men with hematocrit above 54% or untreated severe obstructive sleep apnea.

Failure to monitor is both clinically negligent and a marker of illegitimate prescribing. Clinics supplying testosterone without baseline or follow-up labs, like Biogenesis, are operating outside every published guideline.

How Performance-Enhancement Dosing Differs

The doses documented in performance-enhancement contexts are typically two to ten times the therapeutic range. Testosterone cypionate at 400 to 600 mg per week, sometimes combined with nandrolone or HGH, produces supraphysiological serum levels that would be immediately apparent on any monitoring lab. Research in the British Journal of Sports Medicine found that testosterone doses of 600 mg/week produce mean serum total testosterone levels exceeding 2,400 ng/dL, roughly four times the upper limit of normal physiological range. Those levels are clinically indefensible as replacement therapy and constitute performance enhancement by any medical or regulatory standard.

The Biogenesis Clinic Model and Why It Failed Every Legal Test

Biogenesis operated as a hybrid anti-aging and sports performance clinic. It prescribed testosterone, HGH, and peptides without standard diagnostic workups, maintained records that contradicted standard medical practice, and supplied substances directly rather than routing prescriptions through licensed pharmacies.

How Anti-Aging Clinics Can Cross Legal Lines

A licensed physician operating a TRT clinic is legal. The legal exposure arises when the prescribing lacks a documented diagnosis, when doses exceed physiological replacement, when the clinic supplies controlled substances without DEA-compliant recordkeeping, or when the patient is an athlete in a sanctioned sport without a TUE. All four factors were present at Biogenesis.

A 2019 study in JAMA Internal Medicine found that approximately 21% of U.S. Men receiving testosterone therapy had no testosterone level measured in the prior 12 months, and 25% had no follow-up testing after initiation, suggesting widespread deviation from guideline-concordant prescribing across the broader TRT market.

Player Liability vs. Clinic Liability

Rodriguez faced league discipline. Bosch faced federal prison. The legal exposure differs by role but both are real. A player who knowingly receives a controlled substance from an unlicensed source bears criminal exposure for possession. A prescriber who knowingly supplies controlled substances for non-medical purposes faces distribution charges carrying mandatory minimum sentences.

The DEA's Diversion Control Division maintains that a prescription for a controlled substance "must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice," as codified at 21 C.F.R. § 1306.04. Biogenesis violated that standard systematically.

What Athletes and TRT Patients Should Take Away

The Rodriguez case is not an argument against testosterone therapy. It is a case study in what happens when testosterone is obtained outside legal and clinical channels, without proper diagnosis, without regulatory compliance, and in violation of governing sport rules.

Any male patient with symptoms of hypogonadism, including fatigue, reduced libido, loss of muscle mass, and morning testosterone below 300 ng/dL on two separate measurements, may be a legitimate candidate for TRT under physician supervision. The Endocrine Society defines biochemical hypogonadism as a consistently low morning serum total testosterone below 300 ng/dL, confirmed on two occasions using a reliable assay.

Athletes in sanctioned sports must confirm their sport's substance list and TUE application process before starting any testosterone therapy, even if medically indicated. The TUE application to MLB, WADA, or USADA requires documentation that the treating physician can provide before the first injection.

For non-athlete patients, the legal path is straightforward: a licensed physician, a confirmed diagnosis, a DEA-compliant pharmacy, and follow-up labs at 3 months. Serum total testosterone measured at 8 a.m. Remains the diagnostic standard, with a target therapeutic range of 400 to 700 ng/dL on treatment.